Wall Street closes at a record for the first time since end of January
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced its annual equity grant to employees, including executive officers and non-employee directors, according to a press release statement disclosed in a recent SEC filing. The micro-cap company, with a market capitalization of just $6.25 million, maintains a healthy balance sheet with more cash than debt despite facing profitability challenges.
On Monday, the company granted each non-employee director 10,000 options with an exercise price set at $3.68 per share, reflecting the closing price of Sonoma Pharmaceuticals’ common stock on the same day. These options will vest in three equal parts on the first, second, and third anniversaries of the grant date.
In addition, Chief Executive Officer Amy Trombly received 10,000 restricted stock units (RSUs), and Chief Financial Officer Jerry Dvonch received 5,000 RSUs. The RSUs are scheduled to vest on the third anniversary of the grant date, or earlier upon a change of control or as otherwise provided in the executive officers’ employment agreements.
The equity grants are intended to recognize employees who meet certain employment criteria and to retain key personnel. Sonoma Pharmaceuticals is incorporated in Delaware and is listed on the Nasdaq Stock Market under the ticker SNOA.
This information is based on a press release statement contained in the company’s recent SEC filing.
In other recent news, Sonoma Pharmaceuticals has registered its manufacturing facility under the FDA’s Modernization of Cosmetics Regulation Act of 2022. This registration includes the listing of its Microcyn-based facial spray, allowing the company to manufacture and commercialize these products as cosmetics within the United States. This strategic move expands Sonoma’s reach beyond its existing FDA medical device establishment registration. The company aims to tap into the U.S. cosmetics and dermatology consumer markets, which are projected to grow significantly in the coming years. Industry reports suggest that these markets could reach nearly $40 billion by 2030. This development marks a significant step for Sonoma Pharmaceuticals in broadening its market presence. The registration under MoCRA is seen as a crucial advancement for the company’s business strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.